In a report launched immediately, Cory Jubinville, PhD from LifeSci Capital maintained a Purchase ranking on Crinetics Prescription drugs (CRNX – Analysis Report), with a value goal of $57.00. The corporate’s shares closed yesterday at $15.97.
In accordance with TipRanks, Jubinville, PhD is an analyst with a median return of -12.9% and a 16.67% success fee. Jubinville, PhD covers the Healthcare sector, specializing in shares reminiscent of Crinetics Prescription drugs, Verve Therapeutics, and Tenaya Therapeutics.
At the moment, the analyst consensus on Crinetics Prescription drugs is a Sturdy Purchase with a median value goal of $45.14, representing a 182.65% upside. In a report launched on August 30, Oppenheimer additionally initiated protection with a Purchase ranking on the inventory with a $40.00 value goal.
See the highest shares advisable by analysts >>
CRNX market cap is presently $883.7M and has a P/E ratio of -4.69.
Primarily based on the current company insider exercise of 39 insiders, company insider sentiment is destructive on the inventory. Because of this over the previous quarter there was a rise of insiders promoting their shares of CRNX in relation to earlier this yr. Final month, Struthers Richard Scott, the President & CEO of CRNX purchased 10,000.00 shares for a complete of $19,100.00.
TipRanks has tracked 36,000 firm insiders and located that a couple of of them are higher than others in the case of timing their transactions. See which 3 shares are most certainly to make strikes following their insider actions.
Crinetics Prescription drugs, Inc. operates as a scientific stage pharmaceutical firm targeted on the invention, growth, and commercialization of novel therapeutics for uncommon endocrine illnesses and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the remedy of acromegaly. It’s also growing different oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, in addition to an oral nonpeptide ACTH antagonist for the remedy of Cushing’s illness. The corporate was based by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Learn Extra on CRNX: